Noerr advises European Investment Bank on €75m financing of CureVac

A Noerr team headed by Michael Schuhmacher and Andreas Naujoks has advised the European Investment Bank (EIB) in connection with the agreement on a €75 million loan to biopharmaceutical company CureVac. 

The loan will support CureVac, a pioneer in the preclinical and clinical development of mRNA-based drugs, in its ongoing activities to develop vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections.

In addition, the loan will support the Company's efforts to expand its existing Good Manufacturing Practice certified production capabilities and accelerate the completion of its fourth production site in Tübingen, Germany. The EIB financing will be provided in three €25 million tranches upon completion of pre-defined milestones.

Advisors to the European Investment Bank

Banking & Finance
Michael Schuhmacher, Andreas Naujoks (team lead), Dorian Legel (Frankfurt)

Capital Markets
Julian Schulze De la Cruz, Dirk Buken (Frankfurt)

Luxembourg Law
Sara Gerling, Arendt & Medernach